ReachMD CME
By ReachMD
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by ReachMD
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 17
Reviews: 0
Episodes: 656
Description
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
| Episode | Date |
|---|---|
|
Optimizing Resectable Melanoma Outcomes Through Multidisciplinary Care and Multimodal Treatment Strategies
|
Apr 26, 2024 |
|
Managing Immunotherapy-Related Adverse Events during Adjuvant Treatment for Resectable Melanoma
|
Apr 26, 2024 |
|
Case Consult: Adjuvant Therapy Following Localized Treatment for Stage III Melanoma
|
Apr 26, 2024 |
|
What Dermatologists & Surgeons Need To Know: Adjuvant Treatment for Resectable Stage III/IV Melanoma
|
Apr 26, 2024 |
|
Navigating Adjuvant ICI Treatment in Stage II Melanoma: A Patient Case Presentation
|
Apr 26, 2024 |
|
What Dermatologists & Surgeons Need To Know: Adjuvant Treatment for Resectable Stage II Melanoma
|
Apr 26, 2024 |
|
Future Directions: Targeting LAG-3 in Melanoma Treatment
|
Apr 26, 2024 |
|
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
|
Apr 26, 2024 |
|
Analyzing Key Data from LAG-3 Combinations in the Treatment of Metastatic Melanoma
|
Apr 26, 2024 |
|
Patient Case: Tailoring First-Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status
|
Apr 26, 2024 |
|
First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
|
Apr 26, 2024 |
|
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
|
Apr 26, 2024 |
|
Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints
|
Apr 26, 2024 |
|
On the Clinic Floor: Addressing the Most Critical Questions of Frontline Clinicians in Multiple Sclerosis Management
|
Apr 25, 2024 |
|
Idiopathic Pulmonary Fibrosis: The Role of Radiology in Accurate and Timely Diagnosis
|
Apr 25, 2024 |
|
Experts on the Ground: Data Updates on Emerging Therapies for IgAN
|
Apr 25, 2024 |
|
Experts on Call: Connecting Specialists and PCPs to Improve Patient-Centered Obesity Management
|
Apr 25, 2024 |
|
Multidisciplinary Approach to Diagnosing and Managing Indolent Systemic Mastocytosis: The Changing Landscape
|
Apr 24, 2024 |
|
Managing Indolent Systemic Mastocytosis: A Multidisciplinary Case Review
|
Apr 24, 2024 |
|
Advancing the Treatment of ATTRv-PN: What's in the Pipeline?
|
Apr 23, 2024 |
|
ATTRv-PN: A Family Affair?
|
Apr 23, 2024 |
|
Shh…Gene-Silencing Therapies for ATTRv-PN
|
Apr 23, 2024 |
|
Diagnosing ATTRv-PN: What's in Your Toolbox?
|
Apr 23, 2024 |
|
Raising the Red Flag: What's Your Index of Suspicion for ATTRv-PN?
|
Apr 23, 2024 |
|
The Multiple Faces of ATTRv-PN
|
Apr 23, 2024 |
|
ATTRv-PN: A Complicated Disease With a Poor Prognosis
|
Apr 23, 2024 |
|
ATTR Amyloidosis: Familial Vs Wild-Type
|
Apr 23, 2024 |
|
GPRC5D-Targeted Bispecifics in Relapsed/Refractory Multiple Myeloma: Practical Expert Consensus on a New Target with Unique Adverse Events
|
Apr 15, 2024 |
|
Making the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying
|
Apr 15, 2024 |
|
Duchenne Muscular Dystrophy: Differentiating Advances in Treatment
|
Apr 15, 2024 |
|
GET REAL: A Guide to Evolving Treatment of nAMD and DME Using Real-World Data
|
Apr 11, 2024 |
|
South Asians With IBD: Underrepresented and Underappreciated
|
Apr 09, 2024 |
|
How Do We Effectively Integrate the Latest VTE Treatment and Secondary Prevention Guidelines Into Clinical Practice?
|
Mar 29, 2024 |
|
Mrs. V.T. Elizabeth: A Case Study on the Secondary Prevention of VTE
|
Mar 29, 2024 |
|
VTE Prophylaxis in Patients at Risk for a Secondary VTE Event - Options?
|
Mar 29, 2024 |
|
Risk Assessment: Who’s Most Susceptible for a Secondary VTE Event?
|
Mar 29, 2024 |
|
Putting It All Together: Coordinating the Multidisciplinary Care Plan for the Patient With VTE
|
Mar 29, 2024 |
|
Case Time! VTE Prophylaxis Post Hip Replacement
|
Mar 29, 2024 |
|
Right from the Onset: PE Diagnosis, Management
|
Mar 29, 2024 |
|
Right from the Onset: DVT Diagnosis, Management
|
Mar 29, 2024 |
|
What Do the Guidelines Suggest for Prophylaxis, and How Do We Implement?
|
Mar 29, 2024 |
|
Case Time! V.T. Edwards: Management of Extended Thromboprophylaxis in the Medically Ill
|
Mar 29, 2024 |
|
What Options Are Available Prophylactically for My Acute and Post-Acute Medically Ill Patients?
|
Mar 29, 2024 |
|
What Is the Acute and Post Acute Risk of VTE in Acute Medically Ill Patients?
|
Mar 29, 2024 |
|
From Awareness to Action: What To Do With a Positive OSA Screen?
|
Mar 29, 2024 |
|
How to Screen for OSA
|
Mar 29, 2024 |
|
Overcoming Hurdles: Effective OSA Screening in Primary Care
|
Mar 29, 2024 |
|
Pre-Operative Vigilance: The Role of OSA Screening in Surgical Safety
|
Mar 29, 2024 |
|
OSA: Exploring the Impact on Morbidity and Mortality
|
Mar 29, 2024 |
|
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
|
Mar 29, 2024 |
|
Extending Treatment Durability With Next-Generation Neovascular AMD Therapies
|
Mar 25, 2024 |
|
Collaboration and Management of HE: Establishing Foundation for Successful Outcomes
|
Mar 22, 2024 |
|
HEar My Needs: Enhancing the Patient and Provider Dialogue
|
Mar 22, 2024 |
|
Equitable HEalth for All: Improving Care for Underserved Populations and Their Unmet Needs
|
Mar 22, 2024 |
|
How Do I Prevent Future Hospital Visits due to HE?
|
Mar 22, 2024 |
|
The Unmet Need for HE Therapy in the African American Community – Why Is This a Concern?
|
Mar 22, 2024 |
|
HElp! AASLD Guidelines Related to Diagnosis of HE
|
Mar 22, 2024 |
|
West HavEn Criteria—Meaningfulness Into Clinical Practice
|
Mar 22, 2024 |
|
Tackling the Unmet Need HEad On—What Does HE Look Like?
|
Mar 22, 2024 |
|
Emerging Therapeutics in ADH1: Progress in Precision Medicine
|
Mar 22, 2024 |
|
Therapeutic Options for ADH1 and Hypoparathyroidism
|
Mar 22, 2024 |
|
CASR and ADH1: Integrating Biology and Genetic Screening
|
Mar 22, 2024 |
|
Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism
|
Mar 22, 2024 |
|
New and Emerging Agents
|
Mar 20, 2024 |
|
Quality Indicators: How Do You Compare? Part 2
|
Mar 20, 2024 |
|
Quality Indicators: How Do You Compare? Part 1
|
Mar 20, 2024 |
|
Don't Flush Another Colonoscopy Down the Toilet
|
Mar 20, 2024 |
|
Patient Education: Telling Is Not Teaching and Listening Is Not Learning
|
Mar 20, 2024 |
|
Another Inadequate Bowel Prep? It May Not Be the Patient's Fault
|
Mar 20, 2024 |
|
Bowel Prep Hesitancy: What's It All About?
|
Mar 20, 2024 |
|
Bowel Preparation Regimens: How Do They Compare?
|
Mar 20, 2024 |
|
Screening Colonoscopy in 2024 and Beyond
|
Mar 20, 2024 |
|
New Frontiers in Optimizing Patient Outcomes in Multiple Sclerosis: Strategies for Early Intervention to Address Progression Independent of Relapse
|
Mar 20, 2024 |
|
How Do We Best Incorporate Latest Guidance in Optimizing Care for the Patient with AF?
|
Mar 15, 2024 |
|
Case Study - New Guideline Recommendations into Clinical Practice for the Patient with AF
|
Mar 15, 2024 |
|
Impact of Social Determinants of Health on Management of AF
|
Mar 15, 2024 |
|
Latest Guidance on Anticoagulation in AF Patient Populations with Comorbidities
|
Mar 15, 2024 |
|
Latest Guidance on Anticoagulation in Special AF Patient Populations
|
Mar 15, 2024 |
|
Anticoagulation Management of AF: What Has Changed?
|
Mar 15, 2024 |
|
AF Screening, Risk Factors, and Diagnosis: What’s New?
|
Mar 15, 2024 |
|
What Are the Latest Updates on the Clinical and Economic Impact of AF?
|
Mar 15, 2024 |
|
What Are the 10 Key Takeaways for the 2023 ACC/AHA/ACCP/HRS Guideline for AF?
|
Mar 15, 2024 |
|
Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
|
Mar 14, 2024 |
|
The Latest Insights into Rare Blood Disorders: Diagnosis and Treatment Strategies
|
Mar 09, 2024 |
|
A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
|
Mar 07, 2024 |
|
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
|
Mar 07, 2024 |
|
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
|
Mar 07, 2024 |
|
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
|
Mar 07, 2024 |
|
Ultrasound Renal Denervation: Interdisciplinary Approach to Better Patient Outcomes
|
Mar 05, 2024 |
|
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
|
Mar 01, 2024 |
|
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
|
Mar 01, 2024 |
|
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
|
Mar 01, 2024 |
|
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
|
Mar 01, 2024 |
|
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
|
Mar 01, 2024 |
|
Intracranial Activity of ROS1 TKIs
|
Mar 01, 2024 |
|
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
|
Mar 01, 2024 |
|
First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
|
Mar 01, 2024 |
|
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
|
Mar 01, 2024 |
|
Integrating Bispecific Antibodies Into Clinical Practice
|
Mar 01, 2024 |
|
Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization
|
Mar 01, 2024 |
|
Considerations for Dosing Bispecific Antibodies
|
Mar 01, 2024 |
|
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
|
Mar 01, 2024 |
|
Preventing CRS and Neurotoxicities Related to Bispecific Antibodies
|
Mar 01, 2024 |
|
Efficacy Data for Bispecific Antibodies in RRMM
|
Mar 01, 2024 |
|
Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
|
Mar 01, 2024 |
|
The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
|
Mar 01, 2024 |
|
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
|
Mar 01, 2024 |
|
Clinical Challenges With Triple-Class or Penta-Refractory MM
|
Mar 01, 2024 |
|
5 Things You Need to Know About Epilepsy & Depression
|
Feb 29, 2024 |
|
Practical Management of Variceal Bleeding and Hepatorenal Syndrome
|
Feb 28, 2024 |
|
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: PARP Inhibitor-Related Adverse Events and Team-Based Care
|
Feb 28, 2024 |
|
Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: Cytogenetic Testing and PARP Inhibition for Maintenance Treatment
|
Feb 28, 2024 |
|
Emerging Data in the Management of Acute Ischemic Stroke/TIA
|
Feb 27, 2024 |
|
The Path Forward: What’s On the Horizon?
|
Feb 27, 2024 |
|
While Antiplatelets Are Good…They Aren’t for Everyone
|
Feb 27, 2024 |
|
Preventing Ischemic Stroke in Today’s World
|
Feb 27, 2024 |
|
The Frontier of Stroke Diagnosis (RapidAI): How Can Artificial Intelligence Improve Acute Care for Ischemic and Hemorrhagic Stroke?
|
Feb 27, 2024 |
|
Emerging Data in the Management of Intracranial Hemorrhage in the Anticoagulated Patient
|
Feb 27, 2024 |
|
ABC-ICH: Does Care Bundling Improve Outcomes for Patients with Intracranial Hemorrhage?
|
Feb 27, 2024 |
|
Implementation of the 2022 AHA/ASA Guideline for the Management of Patients with Spontaneous Intracerebral Hemorrhage—Are You Doing Enough?
|
Feb 27, 2024 |
|
Providing Optimal Care for the Anticoagulated Patient with Intracranial Hemorrhage in the Acute Care Setting: Does the Patient Need Reversal, Repletion, or Surgery?
|
Feb 27, 2024 |
|
Case-Based Management of Hyperkalemia to Optimize RAASi Therapy in Patients with CKD
|
Feb 26, 2024 |
|
Improving Outcomes in Patients with RVO: Tailoring Treatment
|
Feb 21, 2024 |
|
Revolutionizing Care for Patients With T2D and Obesity: From Pathophysiology to Personalized Treatments
|
Feb 20, 2024 |
|
Patient-Centric Approaches to Managing Migraines in the Female Patient
|
Feb 13, 2024 |
|
Expert Answers to Common Questions on Response Matters: Transforming the Standard of Care in CML by Mastering Response-Guided Treatment
|
Feb 13, 2024 |
|
Expert Answers to Common Questions for Tailoring ADC Therapies Across the HER2 Spectrum in Metastatic Breast Cancer
|
Feb 06, 2024 |
|
Incorporating Data Into Practice: Late-Breaking Highlights on G/GEJ Cancers From the 2024 GI Congress
|
Feb 05, 2024 |
|
What Is the Evidence Supporting CLDN18.2 Targeting in Frontline Management of G/GEJ Cancers
|
Feb 05, 2024 |
|
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Positive G/GEJ Cancers?
|
Feb 05, 2024 |
|
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?
|
Feb 05, 2024 |
|
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers
|
Feb 05, 2024 |
|
HER2 & PD-L1: Exploring Clinical Characteristics of G/GEJ Cancers in Relation to Biomarker Positivity
|
Feb 05, 2024 |
|
Systemic Gout Uncovered: Primary Care Perspectives and Solutions
|
Feb 02, 2024 |
|
Putting Data into Clinical Practice
|
Jan 31, 2024 |
|
New TAVR Data – New TAVR Talk Track
|
Jan 31, 2024 |
|
Challenging TAVR Cases
|
Jan 31, 2024 |
|
It’s All About Patient Identification
|
Jan 31, 2024 |
|
Is Amyloid-Targeting Therapy Worth It?
|
Jan 31, 2024 |
|
Do Women Respond Differently to ATT Than Men?
|
Jan 31, 2024 |
|
What Types of Changes, If Any, Should We Expect with Amyloid-Targeting Therapy?
|
Jan 31, 2024 |
|
What Does ARIA Look Like Clinically?
|
Jan 31, 2024 |
|
How Should We Monitor Patients on Amyloid-Targeting Therapy?
|
Jan 31, 2024 |
|
How Do You Counsel Patients About Amyloid-Related Imaging Abnormalities?
|
Jan 31, 2024 |
|
How Much Should We Worry About Amyloid-Related Imaging Abnormalities?
|
Jan 31, 2024 |
|
Which Biomarkers Do You Recommend to Confirm Amyloid Positivity?
|
Jan 31, 2024 |
|
What is the Role of APOE4 Testing in Alzheimer’s Disease?
|
Jan 31, 2024 |
|
What’s the Best Way to Identify Mild Cognitive Impairment and Early Alzheimer’s Disease?
|
Jan 31, 2024 |
|
Which Amyloid-Targeting Therapy is Best?
|
Jan 31, 2024 |
|
What Are the Data Behind ATT?
|
Jan 31, 2024 |
|
Pediatric Narcolepsy: Addressing the Challenges in Its Recognition, Diagnosis, and Management
|
Jan 29, 2024 |
|
Sodium Oxybate in the Management of Narcolepsy: One Molecule, Three Formulations – and the Critical Role of Shared Decision-Making in Its Use
|
Jan 29, 2024 |
|
Expert Answers to Common Questions for Improving the Road to Remission with CAR T-Cell Therapies in Large B-Cell Lymphoma: Considerations for Community Practice
|
Jan 29, 2024 |
|
Putting It All Together: Coordinating the Multidisciplinary Care Plan for the Elderly Patient With Atrial Fibrillation
|
Jan 26, 2024 |
|
The Case of Arthur Frank: How Do We Manage Elderly Patients with Atrial Fibrillation?
|
Jan 26, 2024 |
|
What Anticoagulation Options Are Available To Optimize Care in the Management of Elderly Patients With Atrial Fibrillation?
|
Jan 26, 2024 |
|
How Do I Improve the Ability to Screen, Interpret, and Diagnose Elderly Patients With Atrial Fibrillation?
|
Jan 26, 2024 |
|
The Treatment Pipeline for Primary Biliary Cholangitis: IBAT Inhibition and Beyond
|
Jan 26, 2024 |
|
The Treatment Pipeline for Primary Biliary Cholangitis: Sorting Out the PPARs
|
Jan 26, 2024 |
|
Your Patient's PBC Treatment: Long-Term Monitoring and Management
|
Jan 26, 2024 |
|
Treatment for Primary Biliary Cholangitis: Who's on First, Who's on Second?
|
Jan 26, 2024 |
|
Walk a Mile in My Shoes
|
Jan 26, 2024 |
|
Goals of Treatment for Primary Biliary Cholangitis: A Balancing Act
|
Jan 26, 2024 |
|
Primary Biliary Cholangitis Is Risky Business
|
Jan 26, 2024 |
|
Primary Biliary Cholangitis: A Natural History Lesson
|
Jan 26, 2024 |
|
Primary Biliary Cholangitis vs Primary Sclerosing Cholangitis: Do You Know the Difference?
|
Jan 26, 2024 |
|
Primary Biliary Cholangitis: The Phenotype, It Is a Changin'
|
Jan 26, 2024 |
|
The BeAT Goes On: New Data on Improving Symptoms in HFrEF Patients Using Novel Device Therapy
|
Jan 26, 2024 |
|
Cushing’s Disease: From Diagnosis to Treatment Selection
|
Jan 25, 2024 |
|
Shared Decision-Making in Cushing’s Disease
|
Jan 25, 2024 |
|
Clinical Trial Updates in Cushing’s Syndrome
|
Jan 25, 2024 |
|
Cushing's Disease: Reassessing Recurrence Rates and Implications for Practice
|
Jan 25, 2024 |
|
Cushing’s Syndrome Comorbidities: A Case Study of Interdisciplinary Collaboration
|
Jan 25, 2024 |
|
Establishing a Diagnosis in Cushing’s Syndrome: An Individualized Approach
|
Jan 25, 2024 |
|
Tackling Diagnostic Delay in Cushing’s Syndrome
|
Jan 25, 2024 |
|
When to Screen for Cushing’s Syndrome: Smart & Strategic Screening Approaches
|
Jan 25, 2024 |
|
How Would You Treat?
|
Jan 25, 2024 |
|
Managing TRAEs and Minimizing Hyperglycemia
|
Jan 25, 2024 |
|
Best Practices for Individualizing Treatment Selection
|
Jan 25, 2024 |
|
Understanding Trial Data
|
Jan 25, 2024 |
|
Guideline and Evidence-Based Best Practices for Treatment Sequencing
|
Jan 25, 2024 |
|
Making a Definitive Diagnosis
|
Jan 25, 2024 |
|
Refining Screening and Referral in Frontline Care Settings
|
Jan 25, 2024 |
|
Could Your Patient’s Symptoms Be Acromegaly?
|
Jan 25, 2024 |
|
Recurrence of Cushing’s and the Changing Landscape of Medical Management
|
Jan 25, 2024 |
|
Diagnostic Delay and the Critical Role of Personalized Screening Approaches in Cushing’s Syndrome
|
Jan 25, 2024 |
|
JAK Inhibitor Therapy for Alopecia Areata: Expert Guidance to Fill in the Gaps
|
Jan 24, 2024 |
|
Collaboration Is Key— Strategies for a Multidisciplinary Approach to Anticoagulation Management with VTE
|
Jan 19, 2024 |
|
Implementing VTE Learnings Into Clinical Practice
|
Jan 19, 2024 |
|
Case: Evaluation and Diagnosis of VTE
|
Jan 19, 2024 |
|
Case: Recognizing the Signs & Symptoms of VTE
|
Jan 19, 2024 |
|
Comprehensive Anticoagulation Management for VTE
|
Jan 19, 2024 |
|
Ongoing Oral Anticoagulation Management
|
Jan 19, 2024 |
|
Selecting Anticoagulants for Acute VTE
|
Jan 19, 2024 |
|
Identifying Patients at Risk for VTE
|
Jan 19, 2024 |
|
Collaboration Is Key—Strategies for a Multidisciplinary Approach to Anticoagulation Management for Patients with Atrial Fibrillation
|
Jan 19, 2024 |
|
Case: Approaches to Anticoagulation for Atrial Fibrillation
|
Jan 19, 2024 |
|
Case: Anticoagulation Considerations for Atrial Fibrillation
|
Jan 19, 2024 |
|
Case: Diagnosis & Initial Evaluation of a Patient with Atrial Fibrillation
|
Jan 19, 2024 |
|
Risk Factors & Comorbidities Associated with Atrial Fibrillation
|
Jan 19, 2024 |
|
Comprehensive Anticoagulation Management for Atrial Fibrillation
|
Jan 19, 2024 |
|
Oral Anticoagulation Management in Patients with Atrial Fibrillation
|
Jan 19, 2024 |
|
Initial Approaches: Starting Anticoagulation Treatment
|
Jan 19, 2024 |
|
Identifying Patients at Risk for Atrial Fibrillation
|
Jan 19, 2024 |
|
ASCO/ESMO 2023 Roundtable: Contextualizing the Latest Advances in HER2-Targeted Therapy for Solid Tumors
|
Jan 17, 2024 |
|
Bladder Cancer: HER2-Targeted ADCs for Genitourinary Cancers
|
Jan 17, 2024 |
|
Biliary Tract and Pancreatic Cancer: HER2-Targeted ADCs for Gastrointestinal Cancers
|
Jan 17, 2024 |
|
Endometrial Cancer: HER2-Targeted ADCs: A Promising Approach to Address Unmet Needs
|
Jan 17, 2024 |
|
Ovarian Cancer: Advances in HER2-Targeted ADCs
|
Jan 17, 2024 |
|
Cervical Cancer: HER2-Targeted ADCs – Current Status and Future Directions
|
Jan 17, 2024 |
|
Management Strategies for Treatment-Emergent Adverse Events (TEAEs) in HER2-Altered Advanced Solid Tumors
|
Jan 17, 2024 |
|
Testing for Solid Tumors: Tissue and Liquid Biopsy Approaches Using NGS Technologies for cfDNA and ctDNA Analysis
|
Jan 17, 2024 |
|
Targeting HER2 in Advanced Solid Tumors: A Comprehensive Understanding of the Rationale and Potential Benefits
|
Jan 17, 2024 |
|
Addressing the Unmet Need in HER2-Positive Advanced Solid Tumors: Exploring Response Rates and Duration of Response
|
Jan 17, 2024 |
|
The Gut Microbiome: An Evidence-Based Approach to Managing Recurrent C difficile Infection
|
Jan 17, 2024 |
|
Maximizing Benefit With the Expanding Options for Gastric Cancer: Patient Selection and Management
|
Jan 17, 2024 |
|
Expanding Screening, Improving Treatment Acceptance, and Optimizing Outcomes for Patients with Moderate to Severe Alcohol Use Disorder (AUD)
|
Jan 17, 2024 |
|
Expert Consensus on How Oxybates Influence Cardiovascular Risk in Narcolepsy Patients
|
Jan 12, 2024 |
|
Are Oxybates Safe in Narcolepsy Patients?
|
Jan 12, 2024 |
|
Practical Approach to Incorporation of Oxybates Into Clinical Practice
|
Jan 12, 2024 |
|
Treatment Options for the Management of Narcolepsy
|
Jan 12, 2024 |
|
Life’s Essential 8 Diet Paradigm: The Narcolepsy Connection
|
Jan 12, 2024 |
|
Epidemiology of Cardiovascular Disease In Narcolepsy
|
Jan 12, 2024 |
|
Life’s Essential 8: Healthy Sleep With Narcolepsy
|
Jan 12, 2024 |
|
Challenges in Recognizing and Diagnosing Narcolepsy
|
Jan 12, 2024 |
|
Which Comes First? The Stimulant or the Oxybate?
|
Jan 12, 2024 |
|
Evidence-based Discussion of the New and Emerging Treatment Strategies for Idiopathic Hypersomnia
|
Jan 12, 2024 |
|
Professional Recommendations of Clinically Validated Tools Used to Monitor Response to Treatment in Idiopathic Hypersomnia
|
Jan 12, 2024 |
|
Evolving Treatment Paradigms in Idiopathic Hypersomnia
|
Jan 12, 2024 |
|
Patient Testimonial: A Day In the Life of an Idiopathic Hypersomnia Patient
|
Jan 12, 2024 |
|
Evaluating and Promoting Health in Idiopathic Hypersomnia: Beyond Sleepy
|
Jan 12, 2024 |
|
Idiopathic Hypersomnia and Cardiovascular Health: Too Much of a Good Thing?
|
Jan 12, 2024 |
|
Idiopathic Hypersomnia Insights: A Diagnostic Case Study
|
Jan 12, 2024 |
|
Challenges in Recognizing and Diagnosing Idiopathic Hypersomnia
|
Jan 12, 2024 |
|
Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes
|
Jan 10, 2024 |
|
Patient-Centric Management of Menopausal Symptoms: Improving Outcomes with Individualized Therapy
|
Jan 09, 2024 |
|
Complementary Treatment for Uncontrolled Hypertension: Using a Novel Blood Pressure Procedure
|
Jan 08, 2024 |
|
Applying Novel Strategies to the Treatment of Advanced Renal Cell Carcinoma
|
Jan 05, 2024 |
|
An Update on Biomarkers in NSCLC Clinical Management
|
Jan 05, 2024 |
|
PARP Inhibitors in Prostate Cancer: Improving Patient Outcomes Through Precision Therapy
|
Jan 05, 2024 |
|
Sorting Through the Complexities of Managing Metastatic Colorectal Cancer: Strategies for Individualizing Treatment
|
Jan 04, 2024 |
|
Advancing Care and Improving Survival for Patients with HER2-Positive Breast Cancer
|
Jan 04, 2024 |
|
Application of Motivational Interviewing and Shared Decision-making Techniques in Obesity Management
|
Jan 03, 2024 |
|
Chairperson’s Perspective: CDK 4/6 Inhibitors: Practice-Changing Implications of Targeted Therapies in HR+/HER2- Breast Cancer
|
Dec 31, 2023 |
|
Building a Comprehensive Obesity Care Clinic
|
Dec 27, 2023 |
|
Treating Obesity as a Chronic Disease
|
Dec 27, 2023 |
|
Accelerating Evidence-Based Care in LA SCCHN
|
Dec 22, 2023 |
|
How Modulation of Apoptotic Pathways Can Fill Important Unmet Needs in LA SCCHN
|
Dec 22, 2023 |
|
Transforming MS Management
|
Dec 20, 2023 |
|
The Complexity of Early MS Diagnosis
|
Dec 20, 2023 |
|
The Role of S1P Receptor Agonists in MS: Strategies for Disease Management
|
Dec 20, 2023 |
|
From Prescription to Personalization: An HCP’s Guide to Tailoring MS Therapeutic Management
|
Dec 20, 2023 |
|
Advancements in MRI Technology: Improved Diagnosis and Monitoring of MS
|
Dec 20, 2023 |
|
Navigating the Diagnostic Maze: Strategies for Excluding MS Disease Mimics
|
Dec 20, 2023 |
|
What Do Clinicians Need To Know? Utilizing Clinically Validated Diagnostic Tools to Diagnose MS Earlier
|
Dec 20, 2023 |
|
Missed Opportunities in Multiple Sclerosis Care: Increasing HCP Awareness of Early Diagnostic Delays
|
Dec 20, 2023 |
|
Global Perspectives on PARP inhibitor Combinations in mCRPC Match Play: European vs. US Integration in Practice
|
Dec 20, 2023 |
|
New and Emerging Treatment Paradigms for SCZ Symptom Management: One Size Does Not Fit All
|
Dec 11, 2023 |
|
Identifying and Managing Nonadherence to Antipsychotics in People with Schizophrenia
|
Dec 11, 2023 |
|
Who’s on First: Accurate Recognition of Schizophrenia Candidates That Would Benefit From LAI Antipsychotic Therapy
|
Dec 11, 2023 |
|
Too Soon Is Not Soon Enough: Initiation of LAIs Sooner to Manage Symptoms of Suboptimally Treated Schizophrenia
|
Dec 11, 2023 |
|
Overcoming Clinical Barriers to LAI Administration: Identification of the Negative Stigma Surrounding the Use of Injectable Antipsychotics
|
Dec 11, 2023 |
|
Treating ATTR-CM With a Novel Therapeutic Approach: Understanding the ATTRibutes to Success
|
Dec 11, 2023 |
|
Keeping Pace in Lung Cancer - Breaking Barriers: Advances in Treating EGFR Exon 20 Insertions in NSCLC
|
Dec 11, 2023 |
|
Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects
|
Dec 08, 2023 |
|
Real World Use of RWE in HR+ Metastatic Breast Cancer: The Oncologist Perspective
|
Dec 08, 2023 |
|
Importance of the Patient Perspective on RWE in Formulating SDM Conversations
|
Dec 08, 2023 |
|
Unlocking Insights for Underrepresented Patients: The Role of Real-World Evidence in Addressing Limitations of CDK4/6 Inhibitor RCTs
|
Dec 08, 2023 |
|
RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer
|
Dec 08, 2023 |
|
Distinguishing Between High- and Low-Quality RWE: A Journal Club for the Real World
|
Dec 08, 2023 |
|
Balancing the Scales: The Complementary Roles of RCTs and RWE in Modern Healthcare
|
Dec 08, 2023 |
|
KOL Knockout™: Cancer Pain Management Edition
|
Dec 05, 2023 |
|
Migraine and Women's Health: Migraine and the Whole Female Patient
|
Dec 05, 2023 |
|
Postpartum Depression: A Significant Burden and a Novel Approach to Treatment
|
Dec 05, 2023 |
|
Addressing Issues of CV Mortality in Clinical Trials with IV Iron: Are We Still Getting a Medical Benefit?
|
Dec 01, 2023 |
|
Taking the Patient-Centered Approach to Mycophenolate Risk Mitigation
|
Nov 30, 2023 |
|
Case 3 and Panel- Right Heart Diagnostics in PAH
|
Nov 30, 2023 |
|
Case 2 and Panel- CTEPH and PH
|
Nov 30, 2023 |
|
Case 1 and Panel- Limitations of Risk Assessment
|
Nov 30, 2023 |
|
Panel: Issues Dealing with Left Heart Disease in PH
|
Nov 30, 2023 |
|
Epidemiology and Management of Left Heart Disease Associated PH
|
Nov 30, 2023 |
|
Clinical Trials in HFpEF: What Have They Taught Us?
|
Nov 30, 2023 |
|
HFpEF – Diagnostic Approach Through Case Review
|
Nov 30, 2023 |
|
Panel Discussion: Real-World Issues in CTD-PAH Screening, Diagnosis, and Management
|
Nov 30, 2023 |
|
Screening, Diagnosis, and Treatment of PH-ILD
|
Nov 30, 2023 |
|
Pulmonary Arterial Hypertension and Connective Tissue Disease
|
Nov 30, 2023 |
|
PH-ILD: Diagnosis and Management
|
Nov 30, 2023 |
|
Panel Discussion: Simulated CTEPH Case Conference
|
Nov 30, 2023 |
|
Pulmonary Thromboendarterectomy for CTEPH
|
Nov 30, 2023 |
|
Balloon Pulmonary Angioplasty: Issues and Perspectives
|
Nov 30, 2023 |
|
CTEPH & CTED -Current Epidemiology and Trends
|
Nov 30, 2023 |
|
Case Study: A 62-Year-Old Male With CTEPH
|
Nov 30, 2023 |
|
Panel Discussion: Controversies Arising from 2022 ERS/ESC Guideline Revisions
|
Nov 30, 2023 |
|
US Perspective on ESC/ERS Guidelines
|
Nov 30, 2023 |
|
Overview of Major Changes to ERS/ESC Guidelines for PH
|
Nov 30, 2023 |
|
Case: Peri-Operative Immunotherapy in Early-Stage NSCLC
|
Nov 30, 2023 |
|
Case: Adjuvant Immunotherapy in Localized NSCLC
|
Nov 30, 2023 |
|
Case: Update of Neoadjuvant Therapies for Resectable Lung Cancer
|
Nov 30, 2023 |
|
Questions & Answers from the AHA 2023 Symposium
|
Nov 30, 2023 |
|
The Path Forward: What’s On The Horizon?
|
Nov 30, 2023 |
|
While DOACs are Good for Some Things, They Are Not for Everyone
|
Nov 30, 2023 |
|
While the DOAC Revolution Has Occurred, 40-50% of Patients Remain Untreated... Why?
|
Nov 30, 2023 |
|
The DOAC Revolution: What Have We Learned?
|
Nov 30, 2023 |
|
Panel Discussion: Patient Selection, Emerging Studies and Strategies in ES-SCLC
|
Nov 30, 2023 |
|
Case Study: Managing Common Adverse Events Associated with Second-Line Treatment of ES-SCLC
|
Nov 30, 2023 |
|
Case Study: Sequencing Therapy in ES-SCLC in Special Patient Populations
|
Nov 30, 2023 |
|
Case Study: Treatment Sequencing in Platinum-Sensitive Relapse ES-SCLC
|
Nov 30, 2023 |
|
Case Study: Treatment Sequencing in Platinum-Resistant Relapse ES-SCLC
|
Nov 30, 2023 |
|
Making a Difference: Patient-Centered Ulcerative Colitis Care in the Era of JAK Inhibitors and S1P Modulators
|
Nov 29, 2023 |
|
Building Bridges, Closing Gaps in NASH Care: The Pivotal Role of Gastroenterologists
|
Nov 29, 2023 |
|
Harnessing the NAFLD/NASH Epidemic: Preparing for a New Treatment Paradigm
|
Nov 20, 2023 |
|
Hyperkalemia in CKD and HFrEF…What Am I Missing?
|
Nov 17, 2023 |
|
Keeping Pace in Lung Cancer - HER2: Unveiling New Horizons in NSCLC Treatment
|
Nov 15, 2023 |
|
Revolutionary Approaches to Improving Outcomes in Unresected LA SCCHN
|
Nov 15, 2023 |
|
Let’s Rewind: Recognizing NAFLD/NASH in the Primary Care Clinic
|
Nov 14, 2023 |
|
Advances in Minimally Invasive Screening for Lung Cancer: Breaking Data from Honolulu
|
Nov 10, 2023 |
|
Clinical Implications of the Evidence from IV Iron Trials in Heart Failure
|
Nov 03, 2023 |
|
Case Study: CPET
|
Oct 31, 2023 |
|
Video Demo: Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension - Part 2
|
Oct 31, 2023 |
|
Video Demo: Cardiopulmonary Exercise Testing in Pulmonary Arterial Hypertension - Part 1
|
Oct 31, 2023 |
|
Focus on CTD-PAH and Rheumatology
|
Oct 31, 2023 |
|
Pulmonary Hypertension in Rheumatic Diseases - Part 2
|
Oct 31, 2023 |
|
Pulmonary Hypertension in Rheumatic Diseases - Part 1
|
Oct 31, 2023 |
|
Case Study: CTD-PAH
|
Oct 31, 2023 |
|
Focus on Lung-Disease Associated PH
|
Oct 31, 2023 |
|
Link Between Parenchymal Lung Disease and PH
|
Oct 31, 2023 |
|
Case Study: Group 3 PH Pulmonary Hypertension Due to Chronic Lung Disease
|
Oct 31, 2023 |
|
Focus on CTEPH/CTED
|
Oct 31, 2023 |
|
Diagnosis & Treatment of Chronic Thromboembolic Pulmonary Hypertension
|
Oct 31, 2023 |
|
Case Study: CTEPH
|
Oct 31, 2023 |
|
Management of PAH: Update on the Therapeutic Landscape
|
Oct 31, 2023 |
|
Overview of New ERS/ESC Guideline Recommendations
|
Oct 31, 2023 |
|
MET Inhibition in Metastatic NSCLC “In the Spotlight”
|
Oct 25, 2023 |
|
Should We Look for Gout in the Cardiology Clinic?
|
Oct 24, 2023 |
|
What Are the Emerging Therapies for Managing Gout?
|
Oct 24, 2023 |
|
What’s New About Gout? Rheumatology Perspective
|
Oct 24, 2023 |
|
What’s New About Gout? Nephrology Perspective
|
Oct 24, 2023 |
|
Can You Manage Patients With Uncontrolled Gout More Effectively?
|
Oct 24, 2023 |
|
Treat or Refer: Who Is Responsible for Managing Gout?
|
Oct 24, 2023 |
|
Center of the Target: Which Patients Are Most Likely to Develop Gout?
|
Oct 24, 2023 |
|
Is Managing Gout in the Nephrology Clinic a Challenge?
|
Oct 24, 2023 |
|
Is Gout Hiding in the Nephrology Clinic?
|
Oct 24, 2023 |
|
Gout Beyond the Joints: What’s the Hidden Danger?
|
Oct 24, 2023 |
|
New Insights on Integrating Chronic Migraine Preventatives in Clinical Practice
|
Oct 20, 2023 |
|
Novel and Emerging Chronic Migraine Therapies
|
Oct 20, 2023 |
|
Migraine Treatment Update 2023
|
Oct 20, 2023 |
|
Medication Overuse Headache
|
Oct 20, 2023 |
|
2023 ESC Guideline Updates: Where Are We with Iron Deficiency?
|
Oct 20, 2023 |
|
Targeting TSLP in Severe Asthma: A Case-Based Exploration for the Pulmonologist
|
Oct 18, 2023 |
|
A Practical Look at Cardiorenal Protection for CKD in T2D: Applying Recent Data
|
Oct 18, 2023 |
|
Case Presentation: Management of a Patient with Anticoagulation and Severe Traumatic Injuries
|
Oct 09, 2023 |
|
Trauma in the Anticoagulated Patient: Decreasing Morbidity and Mortality in Severe Injuries
|
Oct 09, 2023 |
|
Who Needs Reversal or Repletion for UGI and LGI Bleeding: Case Presentation
|
Oct 09, 2023 |
|
Severe Gastrointestinal Bleeding: Who Needs Reversal Or Repletion For Upper GI And Lower GI Bleeding?
|
Oct 09, 2023 |
|
Delivery of an ICH Care Bundle: Illustrative Case
|
Oct 09, 2023 |
|
Intracranial Hemorrhage: Decreasing Time to Treatment to Improve Outcomes
|
Oct 09, 2023 |
|
Case Presentation: Management of a Patient with Anti-Factor Xa Associated Intracranial Hemorrhage (ICH)
|
Oct 09, 2023 |
|
Emergency Medicine and Neurocritical Care: Managing Life-Threatening Bleeding in the ED
|
Oct 09, 2023 |
|
A Multidisciplinary Approach to Managing Potassium Levels in Patients with Heart Failure When Optimizing RAASi Therapy in Complex Cases
|
Oct 09, 2023 |
|
What Can I Do to Improve Care of Prostate Cancer Patients at Risk for Inequities?
|
Sep 29, 2023 |
|
What Is the Current State of Disparities in Prostate Cancer Care?
|
Sep 29, 2023 |
|
What Is the Pharmacist’s Role in Managing mHSPC Doublet and Triplet Regimens?
|
Sep 29, 2023 |
|
How Nurses and Advanced Practice Clinicians Can Help Patients Navigate a New mHSPC Diagnosis
|
Sep 29, 2023 |
|
Expert Panel: How Can We Integrate Patient Preference Data To Support Shared Decision-Making Conversations in mHSPC?
|
Sep 29, 2023 |
|
Expert Panel: How Does ADT Intensification for mHSPC Affect Future Therapy Options?
|
Sep 29, 2023 |
|
Expert Panel: Selecting Treatment in mHSPC: Which Treatment for Which Patient?
|
Sep 29, 2023 |
|
Choosing Between Doublets and Triplets in mHSPC: What Is the Data?
|
Sep 29, 2023 |
|
Integrating Evidence and Cultural Sensitivity in Patient-Centric Insomnia Treatments
|
Sep 29, 2023 |
|
Examining Treatment Options for Insomnia: From Orexin to GABA
|
Sep 29, 2023 |
|
Utilizing Assessment Tools in Insomnia
|
Sep 29, 2023 |
|
Exploring the Impact of Insomnia on Daytime Functioning and Cognition
|
Sep 29, 2023 |
|
Patient Perspective: Living With Insomnia
|
Sep 29, 2023 |
|
Sleep Architecture and Neurotransmitters of Sleep
|
Sep 29, 2023 |
|
Targeting TSLP in Severe Asthma: A Case-Based Exploration for the Pulmonologist
|
Sep 28, 2023 |
|
Introducing Novel Agents Into the Armamentarium for Triple-Negative Breast Cancer
|
Sep 26, 2023 |
|
Improving the Odds in Metastatic Castrate-Sensitive Prostate Cancer
|
Sep 26, 2023 |
|
Biomarker Testing in NSCLC: Who, What, When?
|
Sep 26, 2023 |
|
Challenges in Myelodysplastic Syndromes (MDS): Risk Stratification and Integrating Novel Treatment Approaches
|
Sep 26, 2023 |
|
Highlights from Madrid on Perioperative Immunotherapy in Early-Stage NSCLC
|
Sep 25, 2023 |
|
Highlights from Madrid on Targeted Therapy for Advanced NSCLC
|
Sep 25, 2023 |
|
Highlights from Singapore on Immunotherapies in Metastatic NSCLC
|
Sep 25, 2023 |
|
Highlights from Singapore on Immunotherapies in Early-Stage NSCLC
|
Sep 25, 2023 |
|
Highlights from Singapore on Targeted Therapies in NSCLC
|
Sep 25, 2023 |
|
Patient Case: How Would You Treat a Newly Diagnosed PNH Patient with Near Normal Hgb?
|
Sep 22, 2023 |
|
Patient Case: How Would You Treat a Newly Diagnosed PNH Patient?
|
Sep 22, 2023 |
|
Is Long-Term Complement Inhibition Safe and Effective in PNH?
|
Sep 22, 2023 |
|
What Is the Impact of First line PNH Treatment Choice on Risk of Thrombosis
|
Sep 22, 2023 |
|
What Are the Data Supporting First Line C5 Inhibitor Treatment of PNH?
|
Sep 22, 2023 |
|
What Are the Data Supporting First Line C3 Inhibitor Treatment of PNH?
|
Sep 22, 2023 |
|
Keeping Up With the Rapid Emergence of Strategies for Advanced Renal Cell Carcinoma
|
Sep 20, 2023 |
|
Closing the Gap: Personalized Approaches to Cervical Cancer Screening and Treatment
|
Sep 19, 2023 |
|
Reconsidering the Algorithm: Treatment-Resistant DME
|
Sep 15, 2023 |
|
Reconsidering the Algorithm: DME
|
Sep 15, 2023 |
|
Reconsidering the Algorithm: nAMD
|
Sep 15, 2023 |
|
A Look at the Numbers: Cost of Durable Treatments in Retinal Disease
|
Sep 15, 2023 |
|
A Closer Look at Real-World Strategies for Treatment-Resistant DME
|
Sep 15, 2023 |
|
Real-World Outcomes with Durable Treatments for Retinal Diseases
|
Sep 15, 2023 |
|
Clinical Evidence for Durable Treatment of DME
|
Sep 15, 2023 |
|
Clinical Evidence for Durable Treatment of nAMD
|
Sep 15, 2023 |
|
Real-World Treatment of Retinal Disease
|
Sep 15, 2023 |
|
What You Should Know About Managing Your Patients with Both CKD and Hyperkalemia
|
Sep 15, 2023 |
|
Bridging the Gap to Care: What You Need to Know About ATTR-CM Amyloidosis
|
Sep 13, 2023 |
|
Expert Opinion on How the New DMTs Fit into Everyday Clinical Practice
|
Sep 08, 2023 |
|
Evidence-Based Discussion of the New and Emerging DMT Treatment Strategies for MCI
|
Sep 08, 2023 |
|
Professional Recommendations of Clinically Validated Tools Used to Diagnose MCI in AD
|
Sep 08, 2023 |
|
Disparities and Inequities in the Diagnosis and Care of Vulnerable Patient Populations
|
Sep 08, 2023 |
|
Evolving Treatment Paradigms For Mild Cognitive Impairment and Dementia: How New DMTs Will Fit Into Clinical Practice
|
Sep 08, 2023 |
|
Novel and Emerging Disease Modifying Therapies for Mild Cognitive Impairment Due to AD: Efficacy and Safety of New DMTs for MCI
|
Sep 08, 2023 |
|
New Data on the Pathophysiology of MCI and Dementia
|
Sep 08, 2023 |
|
Challenges in Recognizing and Diagnosing MCI in AD Earlier
|
Sep 08, 2023 |
|
What Is the Totality of Evidence for IV Iron Treatment Outcomes in Patients with Heart Failure?
|
Sep 01, 2023 |
|
Addressing Patient Management in ASCVD Risk Reduction: A Collaborative Approach
|
Aug 30, 2023 |
|
Experts Debate: How Novel Excessive Daytime Sleepiness Treatments Fit Into Clinical Practice for Obstructive Sleep Apnea
|
Aug 25, 2023 |
|
Roundtable: Safety and Efficacy Data on New Therapies for Excessive Daytime Sleepiness in Obstructive Sleep Apnea
|
Aug 25, 2023 |
|
Roundtable: Experts Recommend Tools to Diagnose and Monitor Excessive Daytime Sleepiness in Obstructive Sleep Apnea
|
Aug 25, 2023 |
|
The Epidemiology of Sleepiness in Obstructive Sleep Apnea
|
Aug 25, 2023 |
|
Algorithm for Assessing Excessive Daytime Sleepiness in Obstructive Sleep Apnea
|
Aug 25, 2023 |
|
New Treatments for Residual Excessive Daytime Sleepiness in Obstructive Sleep Apnea
|
Aug 25, 2023 |
|
Negative Impacts of Excessive Daytime Sleepiness Due to Obstructive Sleep Apnea
|
Aug 25, 2023 |
|
Case Study: Adjusting STOP-BANG Screening Criteria for Minority Ethnic Groups
|
Aug 25, 2023 |
|
How to Identify Residual Excessive Daytime Sleepiness in Obstructive Sleep Apnea
|
Aug 25, 2023 |
|
Choosing and Sequencing Regimens in Relapsed Multiple Myeloma
|
Aug 25, 2023 |
|
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Daratumumab/Lenalidomide/Dexamethasone (DRd)?
|
Aug 25, 2023 |
|
Case Study: How Do You Manage First Relapse Multiple Myeloma Following Upfront ASCT and Lenalidomide Maintenance?
|
Aug 25, 2023 |
|
Are There Other Novel Approaches or Targeted Therapies for Early Relapse?
|
Aug 25, 2023 |
|
Managing AE and Patient Intolerance With Combination Therapy in Early Relapse Multiple Myeloma
|
Aug 25, 2023 |
|
Monoclonal Antibody-Based Regimens for Early Relapse Multiple Myeloma
|
Aug 25, 2023 |
|
Is There a Role for Novel BCMA-Directed Cellular Therapies in Early Relapsed Multiple Myeloma?
|
Aug 25, 2023 |
|
Carfilzomib-Based Regimens for Early Relapse Multiple Myeloma
|
Aug 25, 2023 |
|
Pomalidomide-Based Regimens in Early Relapse Multiple Myeloma
|
Aug 25, 2023 |
|
Multiple Myeloma At First Relapse: Is My Patient Refractory to Lenalidomide?
|
Aug 25, 2023 |
|
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease – Radiology Module
|
Aug 24, 2023 |
|
Managing ART for Optimal Cardiometabolic Health
|
Aug 21, 2023 |
|
Factors to Consider When Thinking About Switching a Patient's ARV Regimen
|
Aug 21, 2023 |
|
Patients at High Risk for Poor Cardiometabolic Outcomes: Is Switching Regimens an Option?
|
Aug 21, 2023 |
|
My Patient Is Stable on ART, But Has Gained 30 Pounds: What Are My Options?
|
Aug 21, 2023 |
|
ART and Cardiometabolic Health: What's the Connection?
|
Aug 21, 2023 |
|
Weight Creep: The Overlooked Vital Sign in Patients with HIV
|
Aug 21, 2023 |
|
Cardiometabolic Disease in Patients with HIV: Who's at Greatest Risk?
|
Aug 21, 2023 |
|
HIV and Cardiometabolic Health: What's the Connection?
|
Aug 21, 2023 |
|
Expert Panel: What Is the Future of Early Intensification in Localized Prostate Cancer?
|
Aug 18, 2023 |
|
Case Study: How Do We Optimize Treatment Adherence with ARIs in Localized Prostate Cancer?
|
Aug 18, 2023 |
|
How Are ARIs Being Used to Intensify Therapy for High-Risk Localized Prostate Cancer After Local Therapy?
|
Aug 18, 2023 |
|
Can ARIs Be Combined with Radiation Therapy in High-Risk Localized Prostate Cancer?
|
Aug 18, 2023 |
|
What Is the Future of Neoadjuvant ARI Intensification in Localized Prostate Cancer?
|
Aug 18, 2023 |
|
Should We Make Active Surveillance More Active for Localized Prostate Cancer?
|
Aug 18, 2023 |
|
How Do We Identify Patients with Localized Prostate Cancer Who Are at Increased Risk for Developing Metastatic Disease?
|
Aug 18, 2023 |
|
Closing Arguments in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
|
Aug 18, 2023 |
|
Defense: Argument for Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
|
Aug 18, 2023 |
|
Prosecution: Argument for Anti-CTLA-4-based Frontline Combination ICI Treatment of Stage IV Melanoma
|
Aug 18, 2023 |
|
Opening Statements in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
|
Aug 18, 2023 |
|
Closing Arguments in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
|
Aug 18, 2023 |
|
Defense: Argument for Single Agent ICI Adjuvant Treatment of Stage III Melanoma
|
Aug 18, 2023 |
|
Prosecution: Argument for BRAF/MEK-Targeted Adjuvant Treatment of Stage III Melanoma
|
Aug 18, 2023 |
|
Opening Statements in the Case of Targeted Versus ICI Adjuvant Treatment of Stage III Melanoma
|
Aug 18, 2023 |
|
Improving Communication Across Care Settings
|
Aug 14, 2023 |
|
Making the Transition: Managing Patients with Sickle Cell Disease Across the Lifespan
|
Aug 14, 2023 |
|
Preventative Management of Sickle Cell Disease Complications
|
Aug 14, 2023 |
|
Implementing the Sickle Cell Treatment Regimen
|
Aug 14, 2023 |
|
Cell and Gene Therapies for Sickle Cell Disease
|
Aug 14, 2023 |
|
Let’s Discuss Transplantation
|
Aug 14, 2023 |
|
Why Do We Need New Therapies for Sickle Cell Disease?
|
Aug 14, 2023 |
|
A Quick Look at Standard Treatments for Sickle Cell Disease
|
Aug 14, 2023 |
|
Diverse Manifestations of Sickle Cell Disease
|
Aug 14, 2023 |
|
The Burden of Sickle Cell Disease for Patients and Their Families
|
Aug 14, 2023 |
|
BID Oxybate to QHS: What Clinicians and Patients Need to Know
|
Aug 14, 2023 |
|
Can We Talk? Optimizing Patient Buy-In to the Management of Narcolepsy
|
Aug 14, 2023 |
|
Oxybate Therapies: Product Attributes and Patient Preferences
|
Aug 14, 2023 |
|
The Great Debate Surrounding Dietary Sodium: The Peril of Applying Population Statistics to Individual Patients
|
Aug 14, 2023 |
|
Cardiovascular Effects of Oxybate: A 20-Year Safety Record
|
Aug 14, 2023 |
|
The Etiology of CV Issues in Patients with Narcolepsy
|
Aug 14, 2023 |
|
Disrupted Nighttime Sleep: A Long-Night’s Journey Into Day
|
Aug 14, 2023 |
|
Narcolepsy 1 and 2: Recognizing Symptoms Including Excessive Sleepiness and Cataplexy
|
Aug 14, 2023 |
|
Oxybates: 1 Molecule, 3 Formulations – Safety
|
Aug 14, 2023 |
|
Oxybates: 1 Molecule, 3 Formulations – Efficacy
|
Aug 14, 2023 |
|
Clinical and Practical Viability of RWE – What Now?
|
Aug 11, 2023 |
|
What Future Studies Are Out There on the Meaningfulness of Reversal in ICH?
|
Aug 11, 2023 |
|
Meaningfulness of ISTH Chart Audit of In-hospital Mortality for ICH?
|
Aug 11, 2023 |
|
Meaningfulness of ISTH Chart Audit of In-hospital Mortality for GI Bleeds?
|
Aug 11, 2023 |
|
Newest Emerging Data from ISTH: Andexanet Alfa vs. 4F-PCC?
|
Aug 11, 2023 |
|
What’s the Best Available Evidence for Reversal of Life-Threatening Bleeds?
|
Aug 11, 2023 |
|
Anticoagulant-Associated Major Bleeding Is a Significant Problem: How Do I Address?
|
Aug 11, 2023 |
|
Setting the Stage: Case Considerations for Bleeding Management in Anticoagulated Patients
|
Aug 11, 2023 |
|
Hot Topics in Blood-based Cancer Screening: Key Information on Multi-Cancer Early Detection from 2023 Spring Oncology Meetings
|
Aug 10, 2023 |
|
Improving Symptoms in Patients with HFrEF Using Novel Device Therapy
|
Aug 07, 2023 |
|
ASCO 2023 Updates on Targeting HER3 in Breast and Lung Cancers
|
Jul 31, 2023 |
|
Risk Assessment in PAH
|
Jul 28, 2023 |
|
Treatment Approaches to ILD-PH
|
Jul 28, 2023 |
|
Hot Topics from the New ERS/ESC PH Guidelines: Focus on Treatment
|
Jul 28, 2023 |
|
Case: Using the 2022 ESC/ERS Treatment Algorithm in Older Male Patient with Cardiopulmonary Comorbidities
|
Jul 28, 2023 |
|
How Should Cardiopulmonary Comorbidities Influence PH Treatment Strategy?
|
Jul 28, 2023 |
|
Implications of Aggressive in ‘PAH with comorbidities’ Therapy: What Does That Mean?
|
Jul 28, 2023 |
|
Essential Aspects of the New ERS/ESC Treatment Guidelines: Patients With Comorbidities
|
Jul 28, 2023 |
|
Implications of Aggressive Therapy in ‘PAH Without Comorbidities’
|
Jul 28, 2023 |
|
Essential Aspects of the New ERS/ESC Treatment Guidelines: Patients Without Comorbidities
|
Jul 28, 2023 |
|
2022 ERS/ESC PAH Guidelines on Treatment
|
Jul 28, 2023 |
|
2022 ERS/ESC PH Guidelines on Diagnosis
|
Jul 28, 2023 |
|
2022 ERS/ESC PAH Guidelines on Echocardiography
|
Jul 28, 2023 |
|
Hot Topics from the New ERS/ESC Guidelines: Definitions and Risk Assessment
|
Jul 28, 2023 |
|
Essential Aspects of the New ERS/ESC Guidelines on PH Treatment: An Overview
|
Jul 28, 2023 |
|
The HPV Vaccine Announcement for Children and Adolescents: HPV Cancer Prevention Starts with You
|
Jul 27, 2023 |
|
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease – Neurology Module
|
Jul 27, 2023 |
|
Keeping Pace in Hematologic Malignancies: 2023 Contextualizing the Evidence: Newly Diagnosed AML in Difficult-to-Treat Subtypes
|
Jul 24, 2023 |
|
What Is the Future of ADCs in Metastatic TNBC?
|
Jul 21, 2023 |
|
What Do Patients/Caregivers Need To Know About ADCs in Metastatic TNBC?
|
Jul 21, 2023 |
|
How Are We Addressing Unanswered Questions Around ADCs in Metastatic TNBC?
|
Jul 21, 2023 |
|
What Factors Impact Use of ADCs in Special Patient Populations with Metastatic TNBC?
|
Jul 21, 2023 |
|
Metastatic TNBC: Utilizing Biology and Health Disparities to Inform Shared Decision Making
|
Jul 21, 2023 |
|
What Is the Evidence for ADCs in HR-/HER2-Low Metastatic Breast Cancer?
|
Jul 21, 2023 |
|
How Do We Apply Evidence Supporting TROP2 Directed ADCs to the Metastatic TNBC Treatment Paradigm?
|
Jul 21, 2023 |
|
Which TNBC Patients Are Eligible for ADCs?
|
Jul 21, 2023 |
|
ADC Targets: Does Positivity Really Matter?
|
Jul 21, 2023 |
|
New and Emerging Treatment Strategies for MDD: Addressing Emotional Blunting and Other Adverse Events
|
Jul 21, 2023 |
|
Novel Therapeutics Treating the Adverse Events From SSRI and SNRI Monotherapy
|
Jul 21, 2023 |
|
Symptom-Based Treatment Using Measurement-Based Care in Patients With MDD
|
Jul 21, 2023 |
|
MDD Treatment: Decisions With Switching, Augmenting, or Staying the Course
|
Jul 21, 2023 |
|
"Inadequate Response": Suboptimal, Treatment Resistance, and Pseudo Resistance in Individuals with MDD
|
Jul 21, 2023 |
|
Delivering Change: Mechanisms to Address Racial Healthcare Disparities in Multiple Myeloma
|
Jul 21, 2023 |
|
Incorporating Scientific Advances into Myelofibrosis Treatment Plans
|
Jul 21, 2023 |
|
In the Medical Spotlight: Antibody-Drug Conjugates in Advanced HER2-Positive Gastric/Gastroesophageal Junction Cancer
|
Jul 20, 2023 |
|
Optimizing the Use of Immunotherapy in the First-line Maintenance Setting for Metastatic Urothelial Carcinoma
|
Jul 19, 2023 |
|
A Changing Approach to TNBC Management: Patients as Partners in Care
|
Jul 18, 2023 |
|
Questions and Conundrums: What Is the Future of ADCs in HR+/HER2-Low MBC?
|
Jul 17, 2023 |
|
Who Is the Best Candidate for Sequencing Sacituzumab Govitecan Before T-DXd in HR+ Breast Cancer?
|
Jul 17, 2023 |
|
Who Is the Best Candidate for Sequencing Trastuzumab Detruxtecan (T-DXd) First?
|
Jul 17, 2023 |
|
How Do Brain Metastases Affect Your Choice of Systemic Treatment in a Patient with HR+/HER2-low MBC?
|
Jul 17, 2023 |
|
Monitoring and Managing Adverse Effects With ADCs in HR+ Breast Cancer: Strategies To Improve Outcomes
|
Jul 17, 2023 |
|
Selection and Sequencing of ADCs in HR+/HER2-Low MBC
|
Jul 17, 2023 |
|
What Are the Data for TROP2-Targeted ADCs in HR+/HER2-Positive and HER2-Low MBC?
|
Jul 17, 2023 |
|
What Are the Data for HER2-Targeted ADCs in HR+/HER2-Low Metastatic Breast Cancer?
|
Jul 17, 2023 |
|
What Are the Clinical and Therapeutic Implications of the Evolving HER2 Testing Landscape?
|
Jul 17, 2023 |
|
What is the Future of Adjuvant Therapy for Resectable Melanoma?
|
Jul 17, 2023 |
|
How Do Patient Characteristics Impact Adjuvant Therapy in All Stages of Resectable Melanoma?
|
Jul 17, 2023 |
|
How Can We Best Manage irAEs During Adjuvant ICIs for Melanoma? A Case-Based Approach
|
Jul 17, 2023 |
|
Optimizing Adjuvant Treatment for Stage IV Melanoma Patients Rendered NED After Surgery
|
Jul 17, 2023 |
|
Adjuvant Treatment for BRAF+ Stage III Melanoma: A Case Study to Weigh ICI Versus Targeted Therapies
|
Jul 17, 2023 |
|
Which Resected Stage II Melanoma Patients Benefit from Adjuvant ICI Therapy?
|
Jul 17, 2023 |
|
Patient Selection for ADCs in First-Line DLBCL
|
Jul 15, 2023 |
|
Late-Stage Bispecifics and ADCs in DLBCL
|
Jul 15, 2023 |
|
NCCN Guideline Updates in DLBCL
|
Jul 15, 2023 |
|
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
|
Jul 15, 2023 |
|
Antibody-Drug Conjugates in FL
|
Jul 15, 2023 |
|
Bispecific Antibodies in FL
|
Jul 15, 2023 |
|
Individualizing Frontline Treatment
|
Jul 15, 2023 |
|
Application of Data from the ECHELON-1 Trial
|
Jul 15, 2023 |
|
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
|
Jul 15, 2023 |
|
Case 6: Implementing Current Guidelines and Best Practices for Monitoring and Mitigating Immune-Related Adverse Events
|
Jul 14, 2023 |
|
Case 5: Is There a Role for IO-Based Therapy in KRAS-Mutated NSCLC? What About Patients With Co-mutations in STK11 or KEAP1?
|
Jul 14, 2023 |
|
Case 4: In Patients Ineligible for Platinum-Based Chemotherapy, What Is the Ideal IO-Based Approach?
|
Jul 14, 2023 |
|
Case 3: In a PD-L1 Negative Patient, Is There Any Benefit to Using Single Agent IO/Chemotherapy or Dual Agent IO/ Chemotherapy?
|
Jul 14, 2023 |
|
Case 2: In a Patient With PD-L1 1–49%, Should I Use Single Agent IO or Combination IO?
|
Jul 14, 2023 |
|
Case 1: How Should I Choose Between Single-Agent IO or IO/Chemotherapy in Patients With PD-L1 = 50% and No Driver Mutations?
|
Jul 14, 2023 |
|
What’s the Consensus on Cardiorenal Protection for CKD in T2D?
|
Jul 13, 2023 |
|
Applying Evidence to Practice: What Can We Learn from Recent Clinical Trials of IV Iron Use in HF?
|
Jul 07, 2023 |
|
Taking Command of the Treatment of ESA-Refractory, Transfusion-dependent LR-MDS
|
Jul 07, 2023 |
|
New and Emerging Therapies for Complex Epileptic Syndromes
|
Jun 30, 2023 |
|
NSCLC Therapy Management and Biomarker Testing
|
Jun 30, 2023 |
|
Hyperkalemia: Is It Still a Challenge in 2023?
|
Jun 30, 2023 |
|
The Future of Muscular Dystrophy Management: Updates for Limb Girdle Muscular Dystrophy
|
Jun 29, 2023 |
|
Understanding the Biological and Clinical Rationale for PARP Inhibitor Combinations as Potential Treatment for Prostate Cancer
|
Jun 29, 2023 |
|
Emerging PH Therapies: How Will They Impact Treatment Strategies?
|
Jun 28, 2023 |
|
Seralutinib for Treatment of Group 1 PAH
|
Jun 28, 2023 |
|
Imatinib for Group 1 PAH
|
Jun 28, 2023 |
|
The Role of Inhaled Treprostinil For Treatment of PH-ILD
|
Jun 28, 2023 |
|
Gene- and Nano-Therapy for PAH: Could This Be the Future?
|
Jun 28, 2023 |
|
Emerging Therapeutics: The Potential of Targeting the Serotonin Pathway in PAH
|
Jun 28, 2023 |
|
Emerging PH Therapeutics: Ralinepag
|
Jun 28, 2023 |
|
Emerging PH Therapeutics: Vardenafil
|
Jun 28, 2023 |
|
Sotatercept: A Novel Entity with Promising Potential for Treating PAH
|
Jun 28, 2023 |
|
Emerging Novel PH Therapies: Will They Impact Treatment Strategies?
|
Jun 28, 2023 |
|
Treatment of OAB and the Managed Care Professional: Balancing the Double-Edged Sword
|
Jun 27, 2023 |
|
The Future of Muscular Dystrophy Management: Updates for Duchenne Muscular Dystrophy
|
Jun 27, 2023 |
|
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Closing Module
|
Jun 26, 2023 |
|
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Emergency Medicine Module
|
Jun 26, 2023 |
|
Lessening Glaucoma Treatment Burden: Clinical Cases (Part 2)
|
Jun 23, 2023 |
|
Lessening Glaucoma Treatment Burden: Clinical Cases (Part 1)
|
Jun 23, 2023 |
|
Advances in Glaucoma Treatment: MIGS (Part 2)
|
Jun 23, 2023 |
|
Advances in Glaucoma Treatment: MIGS (Part 1)
|
Jun 23, 2023 |
|
Lessening Glaucoma Treatment Burden: Sustained-Release Therapies (Part 2)
|
Jun 23, 2023 |
|
Lessening Glaucoma Treatment Burden: Sustained-Release Therapies (Part 1)
|
Jun 23, 2023 |
|
Lessening Glaucoma Treatment Burden with Topical Therapies: The Evidence (Part 2)
|
Jun 23, 2023 |
|
Lessening Glaucoma Treatment Burden with Topical Therapies: The Evidence (Part 1)
|
Jun 23, 2023 |
|
Advances in Glaucoma Treatment: Novel Topical Therapies
|
Jun 23, 2023 |
|
Conversations About PAH: Latest Developments and Key Insights for 2023 – Case Discussion
|
Jun 21, 2023 |
|
Assessing Response to Targeted Therapy in Non-Advanced Systemic Mastocytosis: How to Distinguish AEs From Disease Symptoms
|
Jun 20, 2023 |
|
When Best Supportive Care Is Not Enough: Who Is Eligible for Targeted Therapy in Non-Advanced Systemic Mastocytosis?
|
Jun 20, 2023 |
|
Rationale for Tyrosine Kinase Inhibitors in Non-Advanced Systemic Mastocytosis
|
Jun 20, 2023 |
|
Who Are the Key Players for a Multidisciplinary Approach to Diagnosis and Management of Non-Advanced Systemic Mastocytosis?
|
Jun 20, 2023 |
|
How Do You Diagnose and Assess Symptom Burden When Non-Advanced Systemic Mastocytosis Is Suspected?
|
Jun 20, 2023 |
|
What Are the Recent Updates to Guideline-Driven Care in Non-Advanced Systemic Mastocytosis?
|
Jun 20, 2023 |
|
Updates in the Field of Non-Advanced Systemic Mastocytosis
|
Jun 20, 2023 |
|
PAH Clinical Consult: Getting to the Heart of PAH
|
Jun 20, 2023 |
|
The When and How of Implementing New Anti-Neutrophil Therapies Into Standard Clinical Practice
|
Jun 16, 2023 |
|
Caregiver Testimonial: A Day in the Life of the Bronchiectasis Patient
|
Jun 16, 2023 |
|
Caregiver Perspective: A Day in the Life of the Bronchiectasis Patient
|
Jun 16, 2023 |
|
Vortex Management: Multiprong and Individualized Treatment Approach
|
Jun 16, 2023 |
|
Vortex Management: Diagnostic Algorithm for the PCP and Specialist
|
Jun 16, 2023 |
|
The Neutrophil and Neutrophil Serine Proteases (NSPs) in Non-CF Bronchiectasis (NCFBE)
|
Jun 16, 2023 |
|
Non-CF Bronchiectasis (NCFBE): Identifying At-Risk Patients
|
Jun 16, 2023 |
|
Non-CF Bronchiectasis (NCFBE): Redefined
|
Jun 16, 2023 |
|
Patient-Centered Communications and Shared Decision-Making in the Management of Obesity
|
Jun 16, 2023 |
|
Can You Use a Dual Checkpoint Inhibitor Regimen in an Unfit Patient With BRAF WT Metastatic Melanoma?
|
Jun 15, 2023 |
|
HPV Vaccination Rates in Mid-Adult and High-Risk Patients: Strategies for Improvement
|
Jun 15, 2023 |
|
How Does Symptom Severity Influence Choice of Frontline Therapy for a Patient with BRAF-Mutated Metastatic Melanoma?
|
Jun 15, 2023 |
|
Frontline Treatment: A Patient With BRAF WT Metastatic Melanoma - What Is the Optimal ICI Regimen?
|
Jun 15, 2023 |
|
Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
|
Jun 09, 2023 |
|
Strategies to Reduce Treatment Burden for Vulnerable Patients with Diabetic Eye Disease
|
Jun 06, 2023 |
|
Overcoming Barriers for Vulnerable Patients with Diabetic Eye Disease
|
Jun 06, 2023 |
|
Phenotyping the ILD-PH Patient To Determine Treatment Strategy
|
May 31, 2023 |
|
Genetic Testing in PAH: Cascade Genetic Testing Approach
|
May 31, 2023 |
|
Case: Applying the DETECT Screening Algorithm
|
May 31, 2023 |
|
How Do We Screen For PAH in Systemic Sclerosis Patients?
|
May 31, 2023 |
|
Why Should We Screen for PAH in Systemic Sclerosis Patients?
|
May 31, 2023 |
|
CTD-PAH: What Is the Focus in 2023?
|
May 31, 2023 |
|
Case: A 54-Year-Old Woman With Progressive Dyspnea
|
May 31, 2023 |
|
Screening and Diagnosis of PAH: Cardiopulmonary Exercise Testing (CPET)
|
May 31, 2023 |
|
Understanding the 4-Strata Approach to Risk Assessment (RA) for Patient Monitoring and Management
|
May 31, 2023 |
|
Understanding the Proposed 3-Strata Approach for Initial Risk Assessment (RA) at Diagnosis
|
May 31, 2023 |
|
Why Aren’t All Physicians Using Regular and Consistent Risk Assessment Protocols With Their PH Patients?
|
May 31, 2023 |
|
Areas: A Look at the Importance of Physical Measurements of the Right Heart
|
May 31, 2023 |
|
What Echo Aspects are Essential to PH Diagnosis?
|
May 31, 2023 |
|
Diagnosing PAH: New Emphases on Imaging Modalities
|
May 31, 2023 |
|
Will Lowering the Hemodynamic Threshold for PH Impact “Discovery” of New Patients?
|
May 31, 2023 |
|
Will you ACCELERATE Patient Outcomes?
|
May 31, 2023 |
|
Case Study: Relatively Late Diagnosis & Management of Rett Syndrome
|
May 26, 2023 |
|
Novel Investigational Treatment Options for Rett Syndrome
|
May 26, 2023 |
|
Living With Rett Syndrome: What to Expect at Each Stage
|
May 26, 2023 |
|
Case Study: Diagnosis, Treatment, and Management of Rett Syndrome
|
May 26, 2023 |
|
Quarterbacking the Interprofessional Team: Optimizing Collaboration and Communication To Enhance Patient Outcome
|
May 26, 2023 |
|
New Hope: Novel and Emerging Treatment Options for Rett Syndrome
|
May 26, 2023 |
|
Recognizing the Early and Subtle Signs and Symptoms of Rett Syndrome
|
May 26, 2023 |
|
Compassionate Communication: Keeping the Patient and Family Informed Throughout the Patient’s Journey Through the Four Stages With Rett Syndrome
|
May 26, 2023 |
|
What You Need to Know About Weight-Loss Medications
|
May 26, 2023 |
|
Case Challenge in Obesity Medical Management
|
May 26, 2023 |
|
Examining Disparities in Diabetic Eye Health
|
May 26, 2023 |
|
The Role of Emerging Therapies for Retinal Disease in Clinical Practice
|
May 15, 2023 |
|
Tackling Fluid Overload in Patients with Heart Failure: Novel Approaches to Remote Monitoring
|
May 15, 2023 |
|
Targeting HER3 in Breast and Lung Cancers: Where We Are and Where We Are Going
|
May 15, 2023 |
|
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Introductory Module
|
May 15, 2023 |
|
Case of the Patient in Midlife: Weighing Potential Changes in ASCCP Guidelines
|
May 12, 2023 |
|
“In Any Case?” The Importance of Iron Repletion
|
May 01, 2023 |
|
Enhancing Adherence with Oral Iron Therapy
|
May 01, 2023 |
|
Iron Supplementation Formulations for Females with ID/IDA: Monitoring Response
|
May 01, 2023 |
|
Strategies to Effectively Manage ID and IDA Throughout the Life Span
|
May 01, 2023 |
|
ID and IDA in Postmenopausal Women
|
May 01, 2023 |
|
All Oral Iron Therapies Are Not Created Equal
|
May 01, 2023 |
|
How a Woman’s Iron Status Today Can Impact a Baby’s Health Tomorrow – and Through the Years
|
May 01, 2023 |
|
Assessing and Addressing ID/IDA: The Need for Guidance
|
May 01, 2023 |
|
Pathogenesis of ID and IDA in Reproductive-Aged Women: Focus on Heavy Menstrual Bleeding
|
May 01, 2023 |
|
Contributors to Iron Status: Serum Ferritin, TSAT, and Hemoglobin
|
May 01, 2023 |
|
The Impact and Importance of Iron Status
|
May 01, 2023 |
|
Why Are the Fetus and Placenta Not Rejected by the Mother? New Insights Into Maternal Anti-Fetal Rejection
|
May 01, 2023 |
|
A Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway
|
Aug 31, 2021 |
|
The Clinical Significance of Imaging in the Management of ADPKD
|
Jun 28, 2021 |
|
What You Need to Know About Influenza Pathways & Novel Mechanisms of Action
|
Sep 06, 2019 |
|
Expert Answers to Common Questions for the Management of Hemophilia A
|
Jul 11, 2019 |